(Q38073629)

28 August 2017

1 reference

title

Beneficial and detrimental effects of glycemic control on cardiovascular disease in type 2 diabetes (English)

1 reference

28 August 2017

cardiovascular disease

1 reference

1 reference

type 2 diabetes

9 December 2023

1

Pam R Taub

1 reference

28 August 2017

Erin Higginbotham

2

1 reference

PubMed ID

23314689

28 August 2017

Robert R Henry

series ordinal

3

1 reference

28 August 2017

1 February 2013

1 reference

Current cardiology reports

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

2

1 reference

28 August 2017

332

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-012-0332-4

28 August 2017

0 references

cites work

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

A summary of the ADVANCE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Glucose control and vascular complications in veterans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Long-term effects of intensive glucose lowering on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Diabetic complications. The importance of glucose control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Pre-diabetes, metabolic syndrome, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

ADVANCE--Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Clinical implications of the ACCORD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Severe hypoglycemia and risks of vascular events and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Insulin use and increased risk of mortality in type 2 diabetes: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Three-year efficacy of complex insulin regimens in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Role of mitochondrial dysfunction in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Alternative markers of hyperglycemia and risk of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Evaluation of Urinary 8-Hydroxydeoxy-Guanosine as a Novel Biomarker of Macrovascular Complications in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0332-4

Comprehensive management of patients with type 2 diabetes: establishing priorities of care.

21 January 2018

1 reference

12 December 2020

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

12 December 2020

An analysis of the University Group Diabetes Study Program: data results and conslusions

1 reference

12 December 2020

Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease

1 reference

12 December 2020

Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47)

1 reference

12 December 2020

Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT).

1 reference

12 December 2020

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial

1 reference

12 December 2020

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

1 reference

12 December 2020

10.1007/S11886-012-0332-4

Identifiers

DOI

1 reference

PubMed ID

23314689

Dimensions Publication ID

28 August 2017

0 references

1 reference

PubMed ID

23314689